E-LIB Suche - Ergebnisse für: Trudel, Suzanne

1

Safety and efficacy of belantamab mafodotin with pembrolizu..:

Suvannasankha, Attaya ; Bahlis, Nizar ; Trudel, Suzanne...
Cancer. , 2024

Link: https://doi.org/10.1002/..

2

P081: Enhancing minimally invasive minimal residual disease..:

Abelman, Dor ; Thiagarajah, Madhuran ; Beaudry, Felix...
Genetics in Medicine Open. 2 (2024) - p. 100963 , 2024

Link: https://doi.org/10.1016/..

3

Belantamab mafodotin, pomalidomide and dexamethasone in ref..:

Trudel, Suzanne ; McCurdy, Arleigh ; Louzada, Martha L....
Nature Medicine. 30 (2024) 2 - p. 543-551 , 2024

Link: https://doi.org/10.1038/..

4

Single‐agent belantamab mafodotin in patients with relapsed..:

Nooka, Ajay K. ; Cohen, Adam D. ; Lee, Hans C....
Cancer. 129 (2023) 23 - p. 3746-3760 , 2023

Link: https://doi.org/10.1002/..

5

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIEN..:

Bahlis, Nizar J ; Trudel, Suzanne ; Quach, Hang...
HemaSphere. 7 (2023) S3 - p. e7140563 , 2023

Link: https://doi.org/10.1097/..

6

The Impact of CD34+ Cell Collection Yields for Autologous T..:

Lebel, Eyal ; Lajkosz, Katherine ; Masih-Khan, Esther...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 11 - p. 850-856 , 2023

Link: https://doi.org/10.1016/..

7

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS S..:

Vesole, David H. ; Berdeja, Jesus ; Matous, Jeffrey...
HemaSphere. 7 (2023) S3 - p. e5189693 , 2023

Link: https://doi.org/10.1097/..

8

POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) ..:

Orlowski, Robert Z. ; Bahlis, Nizar J. ; Quach, Hang...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S226 , 2023

Link: https://doi.org/10.1016/..

9

MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relap..:

Orlowski, Robert Z. ; Bahlis, Nizar J. ; Quach, Hang...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S492-S493 , 2023

Link: https://doi.org/10.1016/..

10

Post Salvage Therapy Autologous Transplant for Relapsed Mye..:

Khan, Sahar ; Reece, Donna ; Atenafu, Eshetu G....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 2 - p. e97-e106 , 2023

Link: https://doi.org/10.1016/..

11

P-019 Novel combination immunotherapy for relapsed/ refract..:

Jelinek, Tomas ; Spencer, Andrew ; Krishnan, Amrita...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S43 , 2023

Link: https://doi.org/10.1016/..

12

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE I..:

Mateos, Maria-Victoria ; Bahlis, Nizar J ; Spencer, Andrew...
HemaSphere. 7 (2023) S3 - p. e75458a8 , 2023

Link: https://doi.org/10.1097/..

13

Elranatamab in relapsed or refractory multiple myeloma: the..:

Bahlis, Nizar J. ; Costello, Caitlin L. ; Raje, Noopur S....
Nature Medicine. 29 (2023) 10 - p. 2570-2576 , 2023

Link: https://doi.org/10.1038/..

14

The genetic heterogeneity and drug resistance mechanisms of..:

Vo, Josh N. ; Wu, Yi-Mi ; Mishler, Jeanmarie...
Nature Communications. 13 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

15

P-012: Cevostamab is efficacious and well tolerated in pati..:

Krishnan, Amrita ; Cohen, Adam ; Trudel, Suzanne...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S42-S43 , 2022

Link: https://doi.org/10.1016/..